Lenalidomide Capsule
Product Images NDC 0574-1402

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 0574-1402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg Label (10mg Label)

This is a prescription of Lenalidomide capsules, containing 28 capsules in total. The warning indicates the potential for human birth defects. The manufacturer is Padagis Pharmaceuticals Co. It is important to follow proper handling and dosing instructions for this medication.*

FDA Label Image

15mg Label (15mg Label)

This description is not-available.*

FDA Label Image

2.5 Label (2 5mg Label)

FDA Label Image

20mg Label (20mg Label)

FDA Label Image

25mg Label (25mg Label)

FDA Label Image

5mg Label (5mg Label)

This text appears to be a medication label for Lenalidomide capsules. It includes information such as storage temperature ranges, dosage instructions, the name and address of the pharmaceutical company, and a warning of potential birth defects. The NDC number, prescription reminder, and quantity of capsules are also provided. It is important to consult a healthcare professional for any medical advice or further information about this medication.*

FDA Label Image

Figure 1 (Figure01)

FDA Label Image

Figure02 (Figure02)

FDA Label Image

Figure03 (Figure03)

The text provides data on progression-free survival for Lenalidomide versus placebo in a study, where the median progression-free survival for Lenalidomide was 686 days compared to 225 days for placebo. It also shows the number of subjects at risk and events for progression-free survival, indicating that 97 out of 231 subjects (42.5%) in the Lenalidomide group and 116 out of 229 subjects (51%) in the placebo group experienced events related to progression-free survival.*

FDA Label Image

Figure04 (Figure04)

FDA Label Image

Figure05 (Figure05)

FDA Label Image

Figure06 (Figure06)

This text provides statistical data for a study involving the drug combination of Lenalidomide and Dexamethasone. It includes HR (Hazard Ratio) with confidence interval, Log Rank p-value, and the time to progression in months. The low p-value suggests a statistically significant difference.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.